Klin Farmakol Farm. 2006;20(1):30-35

Headaches induced by pharmacologically active substances or their withdrawal

doc. MUDr. Jaroslav Opavský CSc
Katedra fyzioterapie a algoterapie Fakulty tělesné kultury Univerzity Palackého v Olomouci

Drug-induced headaches represent a common complaint in clinical practice. A generally accepted list of pharmacologically active substances inducing headache is included in the revised International Classification of Headache Disorders (ICHD-II). It presents an up-to-date overview of drugs (and other substances) with a risk of inducing headache during their administration or following their withdrawal. The presented paper provides information on the classification and features of headache following administration of individual drugs (or substances) involved. The spectrum of these pharmacologically active substances has been changing over the course of time, and therefore it is important to thoroughly register headache as a side effect of drugs being newly introduced into clinical practice.

Keywords: international classification of headaches, drug-induced headache, side effects of drugs

Published: March 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Opavský J. Headaches induced by pharmacologically active substances or their withdrawal. Klin Farmakol Farm. 2006;20(1):30-35.
Download citation

References

  1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalagia 2004; 24 (Suppl 1): 1-160.
  2. Opavský J, Keller O, Kotas R, Mastík J, Marková J, Rejda J, Waberžinek G. Česká verze revidované Mezinárodní klasifikace bolestí hlavy (ICHD-II) navržené a předložené Mezinárodní společností pro bolesti hlavy. Čes a slov Neurol Neurochir 2005; 68/101: 133-138.
  3. Lance JW, Goadsby PJ. Mechanism and Management of Headache, 6th ed. Oxford: Butterworth-Heinemann, 1998: 206-225.
  4. Newman LC, Salomon S. Infectious, toxic, and metabolic headache. In: Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff´s Headache, 7th ed. Oxford - New York, Oxford Univ Press, 2001: 434-446.
  5. Silberstein SD, Saper JR, Freitag FG. Migraine: diagnosis and treatment. In: Silberstein SD, Lipton RB, Dalessio DJ, eds. Wolff´s Headache, 7th ed. Oxford - New York, Oxford Univ Press, 2001: 121-237.
  6. Mata P, Alonso R, Badimon J. Benefits and risks of simvastatin in patiens with familial hypercholesterolaemia. Drug Saf 2003; 26: 769-786. Go to original source... Go to PubMed...
  7. Iversen HK. Human migraine models. Cephalalgia 2001; 21: 781-785. Go to original source... Go to PubMed...
  8. Fritsche G, Eberl A, Katsarava Z, Limmroth V, Diener HC. Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol 2001; 45: 229-235. Go to original source... Go to PubMed...
  9. Limmroth V, Katsarava Z, Fritsche G, Pezywara S, Diener HC. Features of medication overuse of different acute headache drugs. Neurology 2002; 59: 1011-1014. Go to original source... Go to PubMed...
  10. Relja G, Granato A, Maria Antonello R, Zorzon M. Headache induced by chronic substance use: analysis of medication overused and minimum dose required to induce headache. Headache 2004; 44: 148-153. Go to original source... Go to PubMed...
  11. Katsarava Z, Diener HC, Limmroth V. Medication overuse headache: a focus on analgesics, ergot alkaloids and triptans. Drug Saf 2001; 24: 921-927. Go to original source... Go to PubMed...
  12. Evers S, Suhr B, Bauer B, Grotemeyer KH, Husstedt IW. A retrospective long-term analysis of the epidemiology and features of drug-induced headache. J Neurol 1999; 246: 802-809. Go to original source... Go to PubMed...
  13. Diener HC, Dichgans J, Scholz E, Geiselhart S, Gerber WD, Bille A. Analgesic-induced headache: long-term results of withdrawal therapy. J Neurol 1989; 236: 9-14. Go to original source... Go to PubMed...
  14. Van Zonneveld M, Flink HJ, Verhey E, Senturk H, Zeuzem S, Akarca US, et al. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther 2005; 21: 1163-1171. Go to original source... Go to PubMed...
  15. Khromov A, Segal M, Nissinoff J, Fast A. Migraines linked to interferon-beta treatment of multiple sclerosis. Am J Phys Med Rehabil 2005; 84: 644-647. Go to original source... Go to PubMed...
  16. Ver Nooy RA, Mangrum JM. Azimilide, a novel oral class III antiarrhythmis for both supraventricular and ventricular arrhythmias. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 75-84. Go to original source... Go to PubMed...
  17. Rabkin JG, Mc Elhiney MC, Rabkin R, Ferrando SJ. Modafinil treatment for fatigue in HIV+ patients: a pilot study. J Clin Psychiatry 2004; 65: 1688-1695. Go to original source... Go to PubMed...
  18. Seftel AD. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin Cardiol 2004; 27 (Suppl 1): I 14-I 19. Go to original source... Go to PubMed...
  19. Tsifetaki N, Kitsos G, Paschides CA, Alamanos J, Eftaxias V, Voulgari PV, et al. Oral pilocarpine for the treatment of ocular symptoms in patiens with Sjogren´s syndrome: a randomised 12 week controlled study. Ann Rheum Dis 2003; 62: 1204-1207. Go to original source... Go to PubMed...
  20. Albright TA, Binns HJ, Katz BZ. Side effects and compliance with malaric prophylaxis in children. J Travel Med 2002; 9: 289-292. Go to original source... Go to PubMed...
  21. Barak Y, Swartz M, Levy D, Weizman R. Age-related differences in the side effects profile of citalopram. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 545-548. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.